Infant Bacterial Therapeutics meddelar att rekryteringen till den första delen av fas III studien är klar - en uppdatering om den kliniska utvecklingen av IBP-9414
February 10, 2021 09:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) kan idag meddela att företaget nu har uppnått en viktig milstolpe genom att ha rekryterat 300 barn i den pågående kliniska fas III-studien av IBP-9414. Detta...
Infant Bacterial Therapeutics announces that the recruitment to the first stage of the Phase III Connection Study is completed - an update about the clinical development of IBP-9414
February 10, 2021 09:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) announces that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Japan
February 09, 2021 14:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att det Japanska Patentverket beslutat utfärda ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar...
Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan
February 09, 2021 14:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2020
February 05, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att förebygga nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn....
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020
February 05, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2020
November 05, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att förebygga nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda barn....
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2020
November 05, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020 VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020 Message from the CEO IBT is currently developing its drug candidate IBP-9414 to prevent necrotizing...